{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:45:43Z","timestamp":1791333943732,"version":"4.3.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01738"],"award-info":[{"award-number":["PI21\/01738"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The Quantiferon Gold Plus (QFT) test, a widely used interferon-\u03b3 release assay (IGRA), diagnoses latent tuberculosis infection (LTBI) with a positivity threshold of \u22650.35 IU\/mL. Results near this cut-off can be challenging to interpret due to variability from immunological, pre-analytical, and technical factors, prompting recommendations for a borderline range to refine diagnosis and reduce overtreatment. This retrospective study analyzed QFT results from 9,944 patients (2019\u20132023), establishing ranges:\u2009&lt;\u20090.2 IU\/mL as negative, 0.2\u20130.35 IU\/mL as borderline negative, 0.35\u20130.7 IU\/mL as borderline positive, and &gt;0.7 IU\/mL as positive. Borderline results occurred in 7.6% of patients, particularly in those born in Africa or South America, and in older individuals. Of 64 patients retested, 60.9% reverted to negative, while 17.1% of borderline negatives later converted to positive or borderline positive. Notably, no active TB cases emerged among those who reverted to negative on repeat testing. These findings emphasize the need for cautious interpretation of borderline QFT results, as their link to active TB progression differs from clear results. The study supports repeat testing of borderline cases to enhance LTBI diagnostic accuracy and inform treatment decisions.<\/jats:p>","DOI":"10.1371\/journal.pone.0330345","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:36:18Z","timestamp":1757352978000},"page":"e0330345","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Refining the diagnostic approach to latent tuberculosis Infection with Quantiferon gold plus: A retrospective analysis of borderline results"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-0453","authenticated-orcid":true,"given":"Alba","family":"Ruedas-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-3308","authenticated-orcid":true,"given":"Juan Mar\u00eda","family":"Herrero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhena","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gonz\u00e1lez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-4275","authenticated-orcid":true,"given":"Paula","family":"L\u00f3pez-Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"5","key":"pone.0330345.ref001","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jinf.2019.08.018","article-title":"QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis","volume":"79","author":"G Sotgiu","year":"2019","journal-title":"J Infect"},{"issue":"2","key":"pone.0330345.ref002","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.advms.2019.09.001","article-title":"Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-\u03b3 release assays: A systematic review and meta-analysis","volume":"64","author":"B Pourakbari","year":"2019","journal-title":"Adv Med Sci"},{"issue":"10","key":"pone.0330345.ref003","article-title":"Performance of Current Diagnostic Tools in Detecting Latent Tuberculosis Among Healthcare Workers: A Systematic Review","volume":"16","author":"R A, D M, Kv L,","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"pone.0330345.ref004","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jiac.2021.08.003","article-title":"Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube tests for patients with active and latent tuberculosis: A prospective cohort study","volume":"27","author":"J-K Lee","year":"2021","journal-title":"J Infect Chemother"},{"key":"pone.0330345.ref005","unstructured":"QIAGEN. QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert [Internet]. 2023 Jan. [cited 02\/18\/2025]. Available from: https:\/\/www.qiagen.com"},{"issue":"5","key":"pone.0330345.ref006","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/14737159.6.5.663","article-title":"QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?","volume":"6","author":"TG Connell","year":"2006","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"pone.0330345.ref007","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/cid\/ciae357","article-title":"Conversion or Reversion of Interferon \u03b3 Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-analysis","volume":"80","author":"M-S Wang","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0330345.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115322","article-title":"Occupational screening for tuberculosis and the use of a borderline zone for interpretation of the IGRA in German healthcare workers","volume":"9","author":"A Schablon","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"pone.0330345.ref009","article-title":"Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions?","volume":"4","author":"M Pai","year":"2007","journal-title":"PLoS Med"},{"issue":"4","key":"pone.0330345.ref010","doi-asserted-by":"crossref","first-page":"1701267","DOI":"10.1183\/13993003.01267-2017","article-title":"Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results","volume":"50","author":"J Brown","year":"2017","journal-title":"Eur Respir J"},{"issue":"12","key":"pone.0330345.ref011","article-title":"Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review","volume":"4","author":"RN van Zyl-Smit","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"pone.0330345.ref012","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1513\/AnnalsATS.201405-188OC","article-title":"Reproducibility of interferon gamma (IFN-\u03b3) release Assays. A systematic review","volume":"11","author":"S Tagmouti","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"pone.0330345.ref013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1164\/rccm.201203-0430OC","article-title":"Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice","volume":"187","author":"JZ Metcalfe","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"pone.0330345.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187313","article-title":"A borderline range for Quantiferon Gold In-Tube results","volume":"12","author":"J Jonsson","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"pone.0330345.ref015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1183\/09031936.00117207","article-title":"Indeterminate test results of T-SPOTTM.TBperformed under routine field conditions","volume":"31","author":"P Beffa","year":"2007","journal-title":"Eur Respir J"},{"issue":"4","key":"pone.0330345.ref016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.00075008","article-title":"Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice","volume":"33","author":"Y Kobashi","year":"2009","journal-title":"Eur Respir J"},{"issue":"6","key":"pone.0330345.ref017","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00272-20","article-title":"Accuracy of QuantiFERON-TB Gold Plus Test for Diagnosis of Mycobacterium tuberculosis Infection in Children","volume":"58","author":"D Buonsenso","year":"2020","journal-title":"J Clin Microbiol"},{"key":"pone.0330345.ref018","unstructured":"\u201c12 de Octubre\u201d University Hospital activity report, 2023. Servicio Madrile\u00f1o de Salud,Department of Health, Community of Madrid. [cited 17 March]. Available at:https:\/\/www.comunidad.madrid\/hospital\/12octubre\/nosotros\/memorias"},{"key":"pone.0330345.ref019","unstructured":"Community of Madrid Statistical Institute. Annual census 2022. [cited 17 March 2025]. Available at: https:\\\\www.madrid.org\\iestadis\\fijas\\estructu\\demograficas\\padron\\pc22ext.htm"},{"key":"pone.0330345.ref020","unstructured":"Regional Register of Tuberculosis Cases of the Community of Madrid. Report for the year 2023. Epidemiological Bulletin of the Community of Madrid. Number 6. Volume 29. June 2024. [cited 17 March 2025]. Available at: https:\/\/www.comunidad.madrid\/servicios\/salud\/tuberculosis"},{"issue":"5","key":"pone.0330345.ref021","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1164\/rccm.201707-1543ED","article-title":"Detecting New Mycobacterium tuberculosis Infection. Time for a More Nuanced Interpretation of QuantiFERON Conversions","volume":"196","author":"N Banaei","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0330345.ref022","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.201302-0365OC","article-title":"Interferon-\u03b3 release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States","volume":"189","author":"SE Dorman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"pone.0330345.ref023","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1164\/rccm.201305-0831OC","article-title":"Challenges with QuantiFERON-TB Gold Assay for Large-Scale, Routine Screening of U.S. Healthcare Workers","volume":"188","author":"ML Slater","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pone.0330345.ref024","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1164\/rccm.201704-0817OC","article-title":"Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection","volume":"196","author":"E Nemes","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"pone.0330345.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00603-21","article-title":"Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis","volume":"59","author":"M Fern\u00e1ndez-Huerta","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"12","key":"pone.0330345.ref026","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01370-21","article-title":"The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting","volume":"59","author":"A Wikell","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"1","key":"pone.0330345.ref027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12879-021-06141-4","article-title":"Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis","volume":"21","author":"JR Ledesma","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0330345.ref028","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"K L\u00f6nnroth","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"pone.0330345.ref029","doi-asserted-by":"crossref","first-page":"1701630","DOI":"10.1183\/13993003.01630-2017","article-title":"Proof of concept that most borderline Quantiferon results are true antigen-specific responses","volume":"50","author":"JW Uzorka","year":"2017","journal-title":"Eur Respir J"},{"key":"pone.0330345.ref030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tube.2018.06.002","article-title":"Borderline QuantiFERON results and the distinction between specific responses and test variability","volume":"111","author":"JW Uzorka","year":"2018","journal-title":"Tuberculosis (Edinb)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:36:25Z","timestamp":1757352985000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330345"}},"subtitle":[],"editor":[{"given":"Frederick","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330345","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}